EN
EN
2026-5-22
Recently, the clinical research project “A Multicenter Study on the Safety and Efficacy of CD73+NK Cell Subpopulation (ZJ-S-0106) in the Rehabilitation Treatment of Mild-to-Moderate Alzheimer’s Disease”, jointly advanced by Shenzhen Zhongjia Biomedical Technology Co., Ltd. and Shenzhen Second People’s Hospital, has successfully passed the National Health Commission’s filing for clinical research on new biomedical technologies (Filing No.: MR-44-2026-00065).
This is an important achievement of industry–university–research translation by Zhongjia Biomedical in collaboration with medical institutions, marking that China’s self-developed cell therapy technology for cognitive disorders has officially entered the international frontier.
Alzheimer’s Disease Treatment Still Faces Key Bottlenecks
Alzheimer’s disease, commonly known as senile dementia, is a neurodegenerative disease of the central nervous system with a high incidence. Patients mainly present with persistent cognitive decline and memory loss, which seriously affects their quality of life.

Current research suggests that abnormal deposition of β-amyloid in the brain is an important cause of neuronal damage and aggravated brain inflammation. Most approved drugs can only relieve some symptoms and can hardly stop disease progression at its root, so more effective source-level treatment options are urgently needed in clinical practice.
Core Technology Breakthrough: CD73+NK Cell Subpopulation Precisely Protects Brain Cognitive Function
CD73+NK cell subpopulation (ZJ-S-0016) is a novel allogeneic NK cell preparation with fully independent intellectual property rights owned by Zhongjia Biomedical, and is the core product of this clinical study.
Compared with traditional cell therapy, it offers several key advantages:
It can penetrate the blood–brain barrier and home to key regions such as the hippocampus;
It can directly clear β-amyloid deposition in the brain and intervene in the pathological process at its source;
It helps protect neurons and promote synaptic growth while reducing brain inflammation;
It acts through multiple targets and pathways to achieve neuroprotection and functional repair.

In previous animal studies, the cell preparation showed no obvious acute toxicity or organ damage, significantly improved learning and memory in experimental animals, and markedly reduced β-amyloid deposition in the brain, laying a solid foundation for human clinical research.
Three Years of Independent R&D: National-Level Clinical Research Qualification
From general NK cell research to the targeted development of CD73+NK cell subpopulations and then to Alzheimer’s disease treatment, Zhongjia Biomedical and the clinical team of Shenzhen Second People’s Hospital have spent three years on technical research, completing a series of key tasks such as cell screening, process optimization and safety evaluation, and forming an independently controllable core technology system.
The project passed hospital ethics review and scientific review by the Guangdong Provincial Health Commission, and ultimately obtained the National Health Commission’s filing for clinical research on new biomedical technologies — authoritative recognition of its technical maturity and research standardization.
This clinical study is conducted in multiple centers. In addition to Shenzhen Second People’s Hospital, Union Hospital and Tongji Hospital affiliated with Huazhong University of Science and Technology are also involved. All centers have completed ethics review and carry out implementation and quality control in strict accordance with national standards.
Clinical Research Advancing Steadily, Focusing on Mild-to-Moderate Alzheimer’s Patients
This clinical study will use the allogeneic CD73+NK cell subpopulation injection provided by Zhongjia Biomedical, targeting patients with mild-to-moderate Alzheimer’s disease, with three main objectives:
To comprehensively evaluate the overall safety of the cell therapy;
To clarify the distribution, metabolism and homing characteristics of the cells in the human body;
To preliminarily verify the improvement in cognitive function through cognitive assessment scales and brain imaging examinations.
Compared with conventional NK cell therapy, CD73+NK cell subpopulation features more prominent targeting, clearer neuro-repair effects and more sufficient safety data, and is expected to form a replicable and standardized treatment scheme in the future.
Future Layout: Expanding to More Brain Diseases to Advance Neuro-Repair
According to the person in charge of Zhongjia Biomedical, CD73+NK cell subpopulation therapy is a neuro-repair technology with great clinical potential. After completing standardized clinical research, the team will steadily advance translation of the results, and plans to expand to Parkinson’s disease, post-stroke cognitive impairment, brain injury and other neurological diseases, bringing new treatment options to more patients.
Taking this national filing as an opportunity, Zhongjia Biomedical will continue to deepen its work in cell therapy, strengthen collaborative innovation across industry, academia and research, and promote more self-developed cell technologies toward clinical application, contributing to brain health protection and the development of the biomedical industry.
About Shenzhen Zhongjia Biomedical Technology Co., Ltd.
Shenzhen Zhongjia Biomedical Technology Co., Ltd. is a national high-tech enterprise focusing on cell therapy technology R&D, clinical translation and industrialization, and is also deeply engaged in the R&D and production of various cell culture media, building a complete industrial chain of “technology R&D + product supply + clinical services”. The company owns a 12,000-square-meter free-standing GMP-compliant pharmaceutical building and has large-scale production capacity for various serum-free media and supporting kits for NK cells, T cells, mesenchymal stem cells and iPS cells, with product quality and technology reaching the international forefront. The company has established deep cooperation with multiple top-tier hospitals, focusing on major disease areas such as neurodegenerative diseases and tumors, building an independent, controllable, safe and effective cell therapy product system, and is committed to providing more accessible innovative treatment options for patients.
Focus on MLD: Why Should This Rare Leukodystrophy Be Seen Earlier?
2026-10-23
Can Alzheimer’s Risk Be Reduced? WHO Guidance Highlights Modifiable Dementia Risk Factors
2026-9-28
Alzheimer's Treatment Advances: From Amyloid to Tau Multi-Target Research
2026-9-28
New Progress in Early Alzheimer's Screening: Blood Tests Become an Important Research Direction
2026-9-28
Great News! Another Zhongjia Medium Gets FDA DMF Filing
2026-7-23